iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company headquartered in Singapore, has recently made significant strides in its pursuit of emergency use approval for its sublingual ketamine wafer, Wafermine. This product is being developed for the management of moderate to severe pain and is currently in phase 2 clinical trials. The company’s announcement marks a pivotal moment, as it progresses toward an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), specifically targeting battlefield pain management.
The U.S. government has facilitated a rare emergency regulatory pathway, allowing iX Biopharma to submit an EUA request later this year. This development is particularly noteworthy as it could enable the drug to reach U.S. military personnel ahead of full FDA clearance. Such a move is expected to generate early revenue streams for the company while its phase-three trials continue. The chairman of iX Biopharma underscored the significance of this government declaration, emphasizing that such pathways are uncommon and represent a substantial opportunity for the company.
This advancement follows a recent contract from the U.S. government, which will fund part of the drug’s development and regulatory efforts. The announcement was significant enough to prompt a brief trading halt, which was lifted before the market opened on September 6, 2026. As of that date, the company’s close price was SGD 0.51, with a 52-week high of SGD 0.585 and a low of SGD 0.019. The market capitalization stands at SGD 519,324,832, despite a negative price-to-earnings ratio of -61.597, reflecting the company’s current financial challenges.
iX Biopharma operates through three primary segments: Specialty Pharmaceutical, Chemical Analysis, and Nutraceutical. In addition to Wafermine, the company’s product portfolio includes BnoX, a sublingual buprenorphine wafer for moderate to severe pain; Wafesil and Silcap, both sublingual sildenafil wafers for the treatment of male erectile dysfunction. The company also engages in the promotion and marketing of nutritional and supplement products through pharmacies and online platforms, alongside developing and commercializing nutraceutical products. Furthermore, iX Biopharma provides laboratory services, enhancing its comprehensive approach to healthcare solutions.
Founded in 2008, iX Biopharma has established a presence in Australia, Singapore, and Malaysia, focusing on the development, manufacturing, and commercialization of therapies for acute and breakthrough pain, among other health conditions. The company’s strategic initiatives and recent developments position it as a forward-looking entity in the pharmaceutical and nutraceutical sectors, with a keen focus on addressing critical healthcare needs through innovative solutions.
